Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Jun;9(12):937-946.
doi: 10.4155/bio-2017-0024. Epub 2017 Jun 19.

Performance evaluation of three platforms with ultrasensitive ligand-binding assay potential

Kyra Juliana Cowan  1 , Albert Geiger  2 , Hans Hornauer  2 , Robyn Rourick  1 , Patricia Yanira Siguenza  1
Affiliations

Performance evaluation of three platforms with ultrasensitive ligand-binding assay potential

Kyra Juliana Cowan et al. Bioanalysis. 2017 Jun.

Abstract

Aim: We evaluated three immunoassay-based technologies and their biomarker kits, by determining precision, parallelism and detectability of analytes of interest.

Materials & methods: We compared ultrasensitive assays for three biomarkers: interleukins IL-6, IL-13 and IL-17A using kits obtained from Roche (IMPACT platform - proprietary platform), Singulex (Erenna®) and Quanterix (Simoa™). We defined the true LLOD as the LLOQs, and provided disease-specific parallelism results and detectability levels for endogenous analyte, which were good across platforms, though they varied from analyte to analyte.

Conclusion: We highlight a simplified approach employed for evaluating ultrasensitive kits and provide an overview of the methodologies used to compare available assays. All three platforms are able to detect very low-level analytes. We recommend all three platforms for detection of very low-level analytes.

Keywords: biomarker; immunoassay; ligand-binding assay; parallelism; platform comparison; ultrasensitive.

PubMed Disclaimer

Publication types

LinkOut - more resources